• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patients Characteristics and Preliminary Outcomes of Heart Failure Registry in A Middle-Income Country: Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).一个中等收入国家心力衰竭注册研究的患者特征和初步结果:波斯心血管疾病/心力衰竭注册研究(PROVE/HF)
Galen Med J. 2018 Nov 8;7:e1026. doi: 10.22086/gmj.v0i0.1026. eCollection 2018.
2
One-year mortality outcomes and hospital readmissions of patients admitted with acute heart failure: Data from the Trivandrum Heart Failure Registry in Kerala, India.急性心力衰竭患者的一年死亡率及再入院情况:来自印度喀拉拉邦特里凡得琅心力衰竭登记处的数据。
Am Heart J. 2017 Jul;189:193-199. doi: 10.1016/j.ahj.2017.03.019. Epub 2017 Apr 2.
3
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).射血分数保留的心力衰竭患者的住院负担和住院后死亡率风险:I-PRESERVE 试验(伊贝沙坦治疗心力衰竭和保留射血分数)的结果。
JACC Heart Fail. 2015 Jun;3(6):429-441. doi: 10.1016/j.jchf.2014.12.017. Epub 2015 May 14.
4
Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry.基于 30 天风险标准化死亡率的医院绩效与心力衰竭住院后长期生存的关联:对 Get With The Guidelines-Heart Failure 注册研究的分析。
JAMA Cardiol. 2018 Jun 1;3(6):489-497. doi: 10.1001/jamacardio.2018.0579.
5
In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry.印度南部心力衰竭患者的住院和三年结局:特里凡得琅心力衰竭注册研究。
J Card Fail. 2018 Dec;24(12):842-848. doi: 10.1016/j.cardfail.2018.05.007. Epub 2018 Jun 7.
6
Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry.当代中国心力衰竭住院患者的流行病学、管理和转归:来自中国心力衰竭注册登记研究(China-HF)的结果。
J Card Fail. 2017 Dec;23(12):868-875. doi: 10.1016/j.cardfail.2017.09.014. Epub 2017 Oct 10.
7
8
Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan.日本住院心力衰竭患者射血分数保留、中间范围和降低的临床特征。
ESC Heart Fail. 2019 Jun;6(3):475-486. doi: 10.1002/ehf2.12418. Epub 2019 Mar 3.
9
Prognostic utility of shock index and modified shock index on long-term mortality in acute decompensated heart failure; Persian Registry of cardioVascular diseasE/Heart Failure (PROVE/HF) study.急性失代偿性心力衰竭中休克指数和改良休克指数对长期死亡率的预后价值;波斯心血管疾病登记处/心力衰竭(PROVE/HF)研究。
Acta Cardiol. 2023 Apr;78(2):217-226. doi: 10.1080/00015385.2022.2030554. Epub 2022 Jan 31.
10
Global Variations in Heart Failure Etiology, Management, and Outcomes.全球心力衰竭病因、治疗和结局的差异。
JAMA. 2023 May 16;329(19):1650-1661. doi: 10.1001/jama.2023.5942.

引用本文的文献

1
Healthcare performance for patients with heart failure in Iran: addressing the tip of the iceberg.伊朗心力衰竭患者的医疗保健表现:冰山一角。
BMC Health Serv Res. 2024 Oct 30;24(1):1317. doi: 10.1186/s12913-024-11699-1.
2
Predicting the risk of mortality and rehospitalization in heart failure patients: A retrospective cohort study by machine learning approach.基于机器学习方法的心力衰竭患者死亡和再住院风险预测:回顾性队列研究。
Clin Cardiol. 2024 Feb;47(2):e24239. doi: 10.1002/clc.24239.
3
Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran.伊朗心力衰竭患者使用缬沙坦、依那普利和坎地沙坦的成本效用分析。
Health Econ Rev. 2023 Sep 4;13(1):44. doi: 10.1186/s13561-023-00457-4.
4
Association of digoxin with mortality and rehospitalization in heart failure patients treated with beta-blockers: Results from the Persian Heart Failure Patient Registry.在接受β受体阻滞剂治疗的心力衰竭患者中地高辛与死亡率和再住院率的关联:来自波斯心力衰竭患者登记处的结果
ARYA Atheroscler. 2022 May;18(3):1-10. doi: 10.48305/arya.v18i0.2329.
5
Relation between Hemoconcentration Status and Readmission Plus Mortality Rate Among Iranian Individuals with Decompensated Heart Failure.伊朗失代偿性心力衰竭患者血液浓缩状态与再入院率及死亡率之间的关系
Int J Prev Med. 2020 Oct 5;11:163. doi: 10.4103/ijpvm.IJPVM_45_19. eCollection 2020.
6
Design and methodology of heart failure registry: Results of the Persian registry of cardiovascular disease.心力衰竭登记研究的设计与方法:波斯心血管疾病登记研究结果
ARYA Atheroscler. 2019 Sep;15(5):228-232. doi: 10.22122/arya.v15i5.1950.

本文引用的文献

1
Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology.波斯心血管疾病登记处(PROVE):设计与方法
ARYA Atheroscler. 2017 Sep;13(5):236-244.
2
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组编写,欧洲心脏病学会心力衰竭协会(HFA)提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
3
Clinical Characteristics, Management, and Outcomes of Hospitalized Heart Failure in a Chinese Population-The Hong Kong Heart Failure Registry.中国人群心力衰竭住院患者的临床特征、管理和转归:香港心力衰竭注册登记研究
J Card Fail. 2016 Aug;22(8):600-8. doi: 10.1016/j.cardfail.2016.03.007. Epub 2016 Mar 18.
4
Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE).急性心力衰竭患者的临床特征、治疗和结局:来自海湾急性心力衰竭注册研究(海湾 CARE)的观察。
Eur J Heart Fail. 2015 Apr;17(4):374-84. doi: 10.1002/ejhf.245. Epub 2015 Mar 4.
5
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).EURObservational Research Programme:心力衰竭试点调查(ESC-HF Pilot)的区域差异和 1 年随访结果。
Eur J Heart Fail. 2013 Jul;15(7):808-17. doi: 10.1093/eurjhf/hft050. Epub 2013 Mar 28.
6
Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study.伊朗人群中心血管疾病的发病率:伊斯法罕队列研究。
Arch Iran Med. 2013 Mar;16(3):138-44.
7
Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome.急性心力衰竭患者特征、治疗和院内结局:意大利心力衰竭结局注册研究结果。
Eur J Heart Fail. 2012 Nov;14(11):1208-17. doi: 10.1093/eurjhf/hfs117. Epub 2012 Jul 25.
8
Prognostic Factors for Survival at 6-Month Follow-up of Hospitalized Patients with Decompensated Congestive Heart Failure.失代偿性充血性心力衰竭住院患者6个月随访生存的预后因素
ARYA Atheroscler. 2010 Fall;6(3):112-7.
9
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry.射血分数保留的心力衰竭患者的特征:ADHERE-US 注册研究与 ADHERE-国际注册研究的比较。
Eur J Heart Fail. 2011 Sep;13(9):945-52. doi: 10.1093/eurjhf/hfr064. Epub 2011 Jun 28.
10
Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods.急性心力衰竭住院患者的治疗短期生存率:使用倾向评分方法的全球 ALARM-HF 登记研究。
Intensive Care Med. 2011 Feb;37(2):290-301. doi: 10.1007/s00134-010-2073-4. Epub 2010 Nov 18.

一个中等收入国家心力衰竭注册研究的患者特征和初步结果:波斯心血管疾病/心力衰竭注册研究(PROVE/HF)

Patients Characteristics and Preliminary Outcomes of Heart Failure Registry in A Middle-Income Country: Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF).

作者信息

Givi Mahshid, Shafie Davood, Garakyaraghi Mohammad, Yadegarfar Ghasem, Roohafza Hamid Reza, Ahmadi Seyed Abdollah, Nouri Fatemeh, Sarrafzadegan Nizal

机构信息

Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

Galen Med J. 2018 Nov 8;7:e1026. doi: 10.22086/gmj.v0i0.1026. eCollection 2018.

DOI:10.22086/gmj.v0i0.1026
PMID:34466426
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8343763/
Abstract

BACKGROUND

The Persian Registry of Cardiovascular disease/Heart Failure (PROVE/HF) aimed to studied the demographic, clinical, and diagnostic characteristics and treatment of patients hospitalized for heart failure (HF) and to follow them for short- and long-term outcomes. Its pilot phase started in 2015 in Isfahan aiming to evaluate its feasibility to be scaled up at the national level in later stages. This article describes the method and preliminary results of the first year registry.

MATERIALS AND METHODS

Information of hospitalized patients with preserved and low ejection fraction, were gathered. Patients were followed for 1, 6, and 12 months. During follow-up, information of the patients' current status, medications used during hospitalization, and in case of death, the cause and place were assessed.

RESULT

PROVE/ HF enrolled 787 patients in the first year. The mean age of patients was 70.74 ±12.01 years, and 60.7% of them were men. The most frequent risk factors for the development of HF in the recruited patients was ischemic heart disease (77.9%), and hypertension (63.7%), respectively. The re-admission rate for patients with HF was at least once in 16% and continued until the fifth to ninth re-admission over a one-year period. Among 787 registered patients, 30.9% died in the first year of follow-up, and the in-hospital mortality was 6.2%. The mean hospitalization period was 4.88 days, and 64.2% were hospitalized for >3 days.

CONCLUSION

The annual rate of re-admission and mortality was high, and the use of medication was less than the recommended one inaccordance with the guidelines for the treatment of heart failure.

摘要

背景

波斯心血管疾病/心力衰竭注册研究(PROVE/HF)旨在研究因心力衰竭(HF)住院患者的人口统计学、临床和诊断特征及治疗情况,并对其进行短期和长期随访。其试点阶段于2015年在伊斯法罕启动,旨在评估后期在全国范围内扩大规模的可行性。本文介绍了第一年注册研究的方法和初步结果。

材料与方法

收集了射血分数保留和降低的住院患者信息。对患者进行了1个月、6个月和12个月的随访。在随访期间,评估患者的当前状态、住院期间使用的药物,以及死亡情况下的死因和死亡地点。

结果

PROVE/HF第一年纳入了787例患者。患者的平均年龄为70.74±12.01岁,其中60.7%为男性。招募患者中发生HF的最常见危险因素分别是缺血性心脏病(77.9%)和高血压(63.7%)。HF患者的再入院率在16%至少有一次,并且在一年期间持续到第五至第九次再入院。在787例登记患者中,30.9%在随访的第一年死亡,住院死亡率为6.2%。平均住院时间为4.88天,64.2%的患者住院时间超过3天。

结论

再入院率和死亡率的年发生率较高,并且根据心力衰竭治疗指南,药物使用少于推荐用量。